235 related articles for article (PubMed ID: 12672509)
1. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
Miklya I; Knoll B; Knoll J
Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
[TBL] [Abstract][Full Text] [Related]
2. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
Knoll J; Miklya I
Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
[TBL] [Abstract][Full Text] [Related]
3. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
Knoll J; Yoneda F; Knoll B; Ohde H; Miklya I
Br J Pharmacol; 1999 Dec; 128(8):1723-32. PubMed ID: 10588928
[TBL] [Abstract][Full Text] [Related]
4. An HPLC tracing of the enhancer regulation in selected discrete brain areas of food-deprived rats.
Miklya I; Knoll B; Knoll J
Life Sci; 2003 May; 72(25):2923-30. PubMed ID: 12697275
[TBL] [Abstract][Full Text] [Related]
5. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons.
Knoll J; Miklya I; Knoll B; Markó R; Kelemen K
Life Sci; 1996; 58(10):817-27. PubMed ID: 8602114
[TBL] [Abstract][Full Text] [Related]
6. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
7. 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged.
Knoll J; Miklya I; Knoll B; Yasusa T; Shimazu S; Yoneda F
Life Sci; 2002 Sep; 71(17):1975-84. PubMed ID: 12175892
[TBL] [Abstract][Full Text] [Related]
8. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
Knoll J
Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
[TBL] [Abstract][Full Text] [Related]
9. Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: rationale for prophylactic (-)deprenyl (selegiline) medication.
Knoll J; Miklya I
Life Sci; 1995; 56(8):611-20. PubMed ID: 7869839
[TBL] [Abstract][Full Text] [Related]
10. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP).
Knoll J; Miklya I
Life Sci; 2016 Dec; 167():32-38. PubMed ID: 27777099
[TBL] [Abstract][Full Text] [Related]
11. A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain.
Knoll J; Baghy K; Eckhardt S; Ferdinandy P; Garami M; Harsing LG; Hauser P; Mervai Z; Pocza T; Schaff Z; Schuler D; Miklya I
Life Sci; 2017 Aug; 182():57-64. PubMed ID: 28623006
[TBL] [Abstract][Full Text] [Related]
12. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
Knoll J
J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
Yoneda F; Moto T; Sakae M; Ohde H; Knoll B; Miklya I; Knoll J
Bioorg Med Chem; 2001 May; 9(5):1197-212. PubMed ID: 11377178
[TBL] [Abstract][Full Text] [Related]
14. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
Miklya I
Mol Psychiatry; 2016 Nov; 21(11):1499-1503. PubMed ID: 27480491
[TBL] [Abstract][Full Text] [Related]
15. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
Miklya I
Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
[TBL] [Abstract][Full Text] [Related]
16. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
Knoll J
J Am Geriatr Soc; 1992 Aug; 40(8):839-47. PubMed ID: 1634730
[TBL] [Abstract][Full Text] [Related]
17. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
Wu RM; Mohanakumar KP; Murphy DL; Chiueh CC
Ann N Y Acad Sci; 1994 Nov; 738():214-21. PubMed ID: 7832430
[TBL] [Abstract][Full Text] [Related]
18. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
19. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Shoulson I
Eur Neurol; 1992; 32 Suppl 1():46-53. PubMed ID: 1425820
[TBL] [Abstract][Full Text] [Related]
20. Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline.
Miklya I
Pharmacol Rep; 2014 Jun; 66(3):453-8. PubMed ID: 24905523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
